Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial

Author(s):
Yamamoto, K.; Takeuchi, T.; Yamanaka, H.; Ishiguro, N.; Tanaka, Y.; Eguchi, K.; Watanabe, A.; Origasa, H.; Iwai, K.; Sakamaki, Y.; Heijde, D. van der; Miyasaka, N.; Koike, T.
Published
2014
Publication type
Article / Letter to editor
Certolizumab pegolMonotherapyRandomized controlled trialRheumatoid arthritisTumor necrosis factor-alpha inhibitor
Date issued
2014-07-31
Language
English
Is part of
Modern Rheumatology (2014), Vol. 24, no. 4, p. 552-560
hdl
1887/103516
doi
10.3109/14397595.2013.843764